Market Watch: The effect of medicare part D coverage on drug use and cost sharing among seniors without prior drug benefits

Health Affairs

Volumn 28, Issue 2, 2009, Pages

  Schneeweiss, Sebastian ^a   Patrick, Amanda R ^a   Pedan, Alex ^b   Varasteh, Laleh ^c   Levin, Raisa ^a   Liu, Nan ^c   Shrank, William H ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Adheris Inc   (United States)

^c Adheris ^*

^d Division of Pharmacoepidemiology and Pharmacoeconomics

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; CLOPIDOGREL; DIGOXIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CHRONIC DISEASE; COPAYMENT; DEMOGRAPHY; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH INSURANCE; MEDICARE; OUT OF POCKET SPENDING; PHARMACY; PRESCRIPTION; PRESCRIPTION DRUG COVERAGE; STATISTICAL ANALYSIS; COST; ECONOMICS; ELDERLY CARE; FEMALE; HUMAN; MALE; MEDICAID; STATISTICS; UNITED STATES;

AGED; AGED, 80 AND OVER; COST SHARING; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICAID; MEDICARE PART D; UNITED STATES;

EID: 66149171369     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.2.w305     Document Type: Article

References (45)

1. D.G. Safran et al., "Prescription Drug Coverage and Seniors: Findings from a 2003 National Survey," Health Affairs 24 (2005): w152-w166 (published online 19 April 2005; 10.1377/hlthaff.w5.152);
2. and S.B. Soumerai et al., "Cost-Related Medication Nonadherence among Elderly and Disabled Medicare Beneficiaries: A National Survey One Year before the Medicare Drug Benefit," Archives of Internal Medicine 166, no. 17 (2006): 1829-1835. (Pubitemid 44455164)
3. Safran et al., "Prescription Drug Coverage and Seniors";
4. and M.A. Steinman, L.P. Sands, and K.E. Covinsky, "Self-Restriction of Medications Due to Cost in Seniors without Prescription Coverage," Journal of General Internal Medicine 16, no. 12 (2001): 793-799. (Pubitemid 34015693)
5. U.S. Department of Health and Human Services, "Over Thirty-eight Million People with Medicare Now Receiving Drug Coverage," Press Release, 14 June 2006, http://www.hhs.gov/news/press/2006pres/20060614.html (accessed 9 December 2008).
6. J. Hoadley et al., "An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans" (Menlo Park, Calif.: Henry J. Kaiser Family Foundation, April 2006);
7. and Social Security Administration, "Medicare Part D Subsidies: Final Rule 20 CFR Part 418," Federal Register 70, no. 250 (2005): 77664-77685.
8. Centers for Medicare and Medicaid Services, "Medicare Program; Medicare Prescription Drug Benefit; Final Rule, 42 CFR," Federal Register 70, no. 18 (2005): 4460.
9. Henry J. Kaiser Family Foundation, "The Medicare Prescription Drug Benefit," Fact Sheet, June 2006, http://www.kff.org/medicare/upload/7044- 04.pdf (accessed 27 January 2009).
10. Hoadley et al., "An In-Depth Examination."
11. W. Yin et al., "The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures," Annals of Internal Medicine 148, no. 3 (2008): 169-177;
12. and F.R. Lichtenberg and S.X. Sun, "The Impact of Medicare Part D on Prescription Drug Use by the Elderly," Health Affairs 26, no. 6 (2007): 1735-1744.
13. Thomson Corporation, Drug Topics Red Book (Montvale, N.J.: Thompson Corporation, 2006);
14. and HHS Office of Inspector General, Medicaid Pharmacy - Additional Analyses of the Actual Acquisition Cost of Prescription Drug Products, Pub. no. A-06-02-00041, September 2002, http://oig.hhs.gov/oas/reports/region6/60200041. pdf (accessed 9 December 2008).
15. See Appendix 1 online at http://content.healthaffairs.org/cgi/content/ full/hlthaff.28.2.w305.DC2.
16. N.K. Choudhry et al., "Warfarin Prescribing in Atrial Fibrillation: The Impact of Physician, Patient, and Hospital Characteristics," American Journal of Medicine 119, no. 7 (2006): 607-615;
17. J.A. Spertus et al., "Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy after Drug-Eluting Stent Placement: Results from the PREMIER Registry," Circulation 113, no. 24 (2006): 2803-2809;
18. and T.J. Lee, M.B. Fennerty, and C.W. Howden, "Systematic Review: Is There Excessive Use of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease?" Alimentary Pharmacology and Therapeutics 20, no. 11-12 (2004): 1241-1251. (Pubitemid 40040071)
19. For more on defined daily doses, see the World Health Organization Collaborating Centre for Drug Statistics Methodology Web site, "The ATC/DDD System," http://www.whocc.no/atcddd/ (accessed 9 December 2008).
20. S. Schneeweiss et al., "On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data: The Policy Maker's versus the Clinician's Perspective," Health Policy 55, no. 2 (2001): 97-109. (Pubitemid 32037121)
21. On the Chronic Disease Score, see M. Von Korff, E.H. Wagner, and K. Saunders, "A Chronic Disease Score from Automated Pharmacy Data," Journal of Clinical Epidemiology 45, no. 2 (1992): 197-203;
22. and S. Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies Using Claims Data," American Journal of Epidemiology 154, no. 9 (2001): 854-864. (Pubitemid 33000813)
23. A.K. Wagner et al., "Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research," Journal of Clinical Pharmacy and Therapeutics 27, no. 4 (2002): 299-309.
24. G.R. Grimmett and D.R. Stirzaker, Probability and Random Processes, 2d ed. (New York: Oxford Science Publications, 1992).
25. Details of the regression analyses are described in Appendix 2, online as in Note 10.
26. See Appendix 3 online; ibid.
27. See Appendices 4 and 5 online; ibid.
28. Yin et al., "The Effect of the Medicare Part D"; and Lichtenberg and Sun, "The Impact of Medicare Part D."
29. M.V. Pauly, "Medicare Drug Coverage and Moral Hazard," Health Affairs 23, no. 1 (2004): 113-122;
30. and Lichtenberg and Sun, "The Impact of Medicare Part D."
31. S. Schneeweiss et al., "Adherence to Statin Therapy under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment," Circulation 115, no. 16 (2007): 2128-2135;
32. and W.H. Shrank et al., "The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions," Archives of Internal Medicine 166, no. 3 (2006): 332-337. (Pubitemid 43244321)
33. S.B. Soumerai et al., "Payment Restrictions for Prescription Drugs under Medicaid: Effects on Therapy, Cost, and Equity," New England Journal of Medicine 317, no. 9 (1987): 550-556;
34. and J. Hsu et al., "Unintended Consequences of Caps on Medicare Drug Benefits," New England Journal of Medicine 354, no. 22 (2006): 2349-2359. (Pubitemid 43801280)
35. K.F. O'Grady et al., "The Impact of Cost Sharing on Emergency Department Use," New England Journal of Medicine 313, no. 8 (1985): 484-490. (Pubitemid 15015077)
36. M.B. McClellan, "Hearing on Generic Drug Utilization in the Medicare Prescription Drug Benefit," testimony before the Senate Special Committee on Aging, 21 September 2006, http://aging.senate.gov/minority/-files/hr166mm.pdf (accessed 9 April 2007).
37. S.B. Soumerai et al., "A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline,"Milbank Quarterly 71, no. 2 (1993): 217-252;
38. and S. Schneeweiss et al., "Clinical and Economic Consequences of a Reimbursement Restriction of Nebulised Respiratory Therapy in Adults: Direct Comparison of Randomised and Observational Evaluations," BMJ 328, no. 7439 (2004): 560.
39. Soumerai et al., "A Critical Analysis."
40. S. Schneeweiss et al., "Quasi-Experimental Longitudinal Designs to Evaluate Drug Benefit Policy Changes with Low Policy Compliance," Journal of Clinical Epidemiology 55, no. 8 (2002): 833-841.
41. Safran et al., "Prescription Drug Coverage."
42. W.H. Shrank et al., "The Effect of Transitioning to Medicare Part D Drug Coverage on Cardiac Medication Use in Seniors Dually Eligible for Medicare and Medicaid," Journal of the American Geriatrics Society 56, no. 12 (2008): 2304-2310.
43. Schneeweiss et al., "Quasi-Experimental Longitudinal Designs."
44. Hoadley et al., "An In-Depth Examination."
45. OIG, Medicaid Pharmacy.